scholarly journals Effect of Natural Feed, Antibiotics, Tannin, Diphenyliodoniumchloride and Salicylic Acid Supplement on Plasma Uric Acid Concentration in Captive Willow Ptarmigan (Lagopus L. Lagopus)

1982 ◽  
Vol 23 (3) ◽  
pp. 468-470
Author(s):  
Ingolf Haussen
Keyword(s):  
Uric Acid ◽  
Salicylic Acid ◽  
Acid Concentration ◽  
Uric Acid Concentration ◽  
Willow Ptarmigan ◽  
Plasma Uric Acid ◽  
Acid Supplement

Acarbose alleviates rise in plasma uric acid concentration induced by sucrose ingestion

2008 ◽  
Vol 46 (04) ◽  
pp. 187-192 ◽  
Author(s):  
Y. Moriwaki ◽  
T. Kobayashi ◽  
T. Inokuchi ◽  
A. Yamamoto ◽  
S. Takahashi ◽  
...  
Keyword(s):  
Uric Acid ◽  
Acid Concentration ◽  
Uric Acid Concentration ◽  
Plasma Uric Acid

Recommandations of the Societe Francaise des Cancers de l’Enfant (SFCE) for the Management of Tumors Lysis Syndrom (TLS) : A Validation Survey.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 5295-5295
Author(s):  
Y. Bertrand ◽  
A. Auvrignon ◽  
B. Nelken ◽  
V. Mialou ◽  
F. Mechinaud ◽  
...  
Keyword(s):  
Uric Acid ◽  
Serum Creatinine ◽  
Acid Concentration ◽  
Lymphoblastic Leukemia ◽  
Urate Oxidase ◽  
Uric Acid Concentration ◽  
Plasma Uric Acid ◽  
Non Hodgkin Lymphoma ◽  
Metabolic Complication ◽  
Oxidase Enzyme

Abstract TLS is a frequent metabolic complication of hematologic malignant diseases which can generate important renal impairment. As described in previous studies (Goldman S.C. et al, Blood2001;97, 2998–3003 and Pui C.H. et al., J.Clin.Oncol.2001;19, 697–704), there are High Risk (HR) patients (pts) of TLS. Rasburicase a recombinant urate oxidase enzyme transforms uric acid into the highly soluble compound allantoin which is then excreted by the kidneys. Rasburicase is highly effective in prevention and treatment of TLS. Based on these studies, the SFCE made the following recommandations for the management of TLS in children. HR pts are defined as : B cell Acute Lymphoblastic Leukemia (ALL), ALL or Acute Myeloblastic Leukemia (AML) with initial leukocyte count of at least 50x109/L, Stage III and IV T or B Non Hodgkin Lymphoma (NHL), any leukemia or NHL with a plasma uric acid concentration of at least 300 mmoles/L if <10 years old or 350 mmoles/L if >10 years old, serum creatinine or lactate deshydrogenase concentration (LDH) exciding twice the upper limit of normal (N), hyperphosphatemia ≥2mmoles/L. These pts are treated by hyperhydratation (3L/m2) ±alkaline and Rasburicase 0,20 mg/kg/d x 5days. Rasburicase is carried on if serum creatinine > 1,5N or phosphatemia >3mmoles/L or plasma uric acid concentration ≥200mmoles/L and until normalization. Low Risk (LR) pts are defined as pts not HR. They are treated by hyperhydratation (3L/m2) and Rasburicase 0,20 mg/kg/d for one day only. Rasburicase is carried on during 4 days or more on the same biological basis as HR pts. In order to check the validity of those guidelines, we are conducting a survey looking at the evolution of the pts managed according to the SFCE recommandations.150 pts are planned for a 6 months study. On July 30th, 39 pts are registred : 25 ALL, 6 AML, 8 NHL (3 Burkitt). At that time there is no SLT complication. Results will be presented at the 2004 ASH Meeting.

scholarly journals Quercetin lowers plasma uric acid in pre-hyperuricaemic males: a randomised, double-blinded, placebo-controlled, cross-over trial

2016 ◽  
Vol 115 (5) ◽  
pp. 800-806 ◽  
Author(s):  
Yuanlu Shi ◽  
Gary Williamson
Keyword(s):  
Blood Pressure ◽  
Uric Acid ◽  
Urinary Excretion ◽  
Acid Concentration ◽  
Fasting Glucose ◽  
Uric Acid Concentration ◽  
Elevated Plasma ◽  
Plasma Uric Acid ◽  
Double Blinded ◽  
Healthy Males

AbstractElevated plasma uric acid concentration is a risk factor for gout, insulin resistance and type 2 diabetes. Quercetin, a flavonoid found in high levels in onions, tea and apples, inhibits xanthine oxidoreductasein vitro, the final step in intracellular uric acid production, indicating that quercetin might be able to lower blood uric acid in humans. We determined the effects of 4 weeks of oral supplementation of quercetin on plasma uric acid, blood pressure and fasting glucose. This randomised, double-blinded, placebo-controlled, cross-over trial recruited twenty-two healthy males (19–60 years) with baseline plasma uric acid concentration in the higher, but still considered healthy, range (339 (sd51) µmol/l). The intervention included one tablet containing 500 mg quercetin daily for 4 weeks, compared with placebo, with a 4-week washout period between treatments. The primary outcome was change in concentrations of plasma uric acid after 2 and 4 weeks; secondary outcome measures were changes in fasting plasma glucose, 24-h urinary excretion of uric acid and resting blood pressure. After quercetin treatment, plasma uric acid concentrations were significantly lowered by −26·5 µmol/l (95 % CI, −7·6, −45·5;P=0·008), without affecting fasting glucose, urinary excretion of uric acid or blood pressure. Daily supplementation of 500 mg quercetin, containing the bioavailable amount of quercetin as present in approximately 100 g red onions, for 4 weeks, significantly reduces elevated plasma uric acid concentrations in healthy males.

Interference of levodopa and its metabolites with colorimetry of uric acid.

1981 ◽  
Vol 27 (5) ◽  
pp. 756-758 ◽  
Author(s):  
D W Bierer ◽  
A J Quebbemann
Keyword(s):  
Uric Acid ◽  
Acid Concentration ◽  
Peak Plasma ◽  
Plasma Concentrations ◽  
Colorimetric Method ◽  
Colorimetric Determination ◽  
Uric Acid Concentration ◽  
Chemical Mechanisms ◽  
Plasma Uric Acid ◽  
Hydroxyphenylacetic Acid

Abstract Reportedly, levodopa (L-DOPA) administration produces spuriously high values for plasma uric acid as measured by the commonly used phosphotungstic acid-hydroxylamine colorimetric method. We confirm this interference, not only by L-DOPA but also by three of its major metabolites: dopamine, 3,4-dihydroxyphenylacetic acid, and 3-methoxy-4-hydroxyphenylacetic acid. However, at therapeutic concentrations in plasma (less than 5 mg/L), the maximum spurious uric acid concentration due to L-DOPA is less than 2 mg/L. Also, at reported peak plasma concentrations of L-DOPA plus three of its major metabolites, the maximum spurious uric acid concentration due to all four compounds combined is less than 8.5 mg/L. Therefore, the hyperuricemia observed with this method in some patients who are chronically receiving L-DOPA cannot be attributed only to interference by L-DOPA and its metabolites in the colorimetric determination of uric acid. Evidently L-DOPA may increase laboratory values for plasma uric acid concentrations, both by pharmacological and chemical mechanisms.

Sign in / Sign up

Export Citation Format

Share Document